demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID-19 mild to moderate
antiandrogenic
progesterone Ghandehari

5 studies excluded by filtering options 0

6345 Kintor Proxalutamide, 0 010selection pending
6487 Lazzeri, 2021 0130selection pending
7425 Cadegiani (male patients), 2020 013selection pending
7440 Cadegiani, 2021 013selection pending
7998 Cadegiani (female patients), 2021 213excludedhigh risk of bias